Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Genprex, Inc.GNPX · Entity 8441 | EVP GC Chief Strategy Officer | April 21, 2023 | April 24, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Genprex, Inc.
Report date April 21, 2023 · Filed April 24, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 265,000 |
Reported balance
After 2023-04-21 transaction · row 1
1 source rowRow 1 · 2023-04-21 · Purchase · Acquired 20,000 · Balance 265,000 F1: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.06 to $1.08 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.06 to $1.08 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 21, 2023 Filed Apr 24, 2023 09:00 UTC | Genprex, Inc. GNPX · Entity 8441 | PurchaseCommon Stock | 20,000 | $1.07 | $21,478.00 |
DisclosureSEC source: 0001437749-23-010869 · rdgdoc.xml · nonDerivative · entry 1 VACZY CATHERINE M · CIK 0001177176 · EVP GC Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,000 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.06 to $1.08 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 18, 2023 Filed Feb 22, 2023 18:36 UTC | Genprex, Inc. GNPX · Entity 8441 | GrantCommon Stock | 245,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-004243 · rdgdoc.xml · nonDerivative · entry 1 VACZY CATHERINE M · CIK 0001177176 · EVP GC Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,000 F1 · shares: This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan and vests in installments of 50% on the first anniversary of the date of grant and the remaining 50% on the second anniversary of the date of grant. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:43 UTC | Genprex, Inc. GNPX · Entity 8441 | GrantStock Option (right to buy) · Derivative | 325,000 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001437749-22-002752 · rdgdoc.xml · derivative · entry 1 VACZY CATHERINE M · CIK 0001177176 · EVP GC Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,000 Underlying: Common Stock · 325,000 shares Expires 2032-02-04 F1 · derivative.exercise_date: The option (the "Option") was granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan (the "Plan"). The Option shall vest and become exercisable as to one third (1/3) of the total number of shares (the "Shares") of the Company's common stock, $.001 par value subject to the Option on February 4, 2023 (the "Vesting Commencement Date") and thereafter shall vest and become exercisable as to an additional 1/24 of the remaining Shares subject to the Option on each monthly anniversary of the Vesting Commencement Date until fully vested and exercisable, in each case provided that the Optionee continues to serve as a Service Provider (as defined in the Plan) through the applicable vesting date. Read SEC document |
| March 19, 2021 Filed Mar 23, 2021 16:48 UTC | Genprex, Inc. GNPX · Entity 8441 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $5.08 | $0.00 |
DisclosureSEC source: 0001437749-21-006914 · rdgdoc.xml · derivative · entry 1 VACZY CATHERINE M · CIK 0001177176 · EVP GC Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-03-19 F1 · derivative.exercise_date: One third (1/3) of the Shares subject to the Option shall vest on each annual anniversary of March 19, 2021 so that one hundred percent (100%) of the shares subject to the Option are vested on the third anniversary of March 19, 2021, provided that the optionee continues to serve as a Service Provider (as defined in Genprex, Inc. 2018 Equity Incentive Plan) through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.